Japan, a manufacturing powerhouse that has long been known for its rigor and high quality, has recently been exposed to a shocking scandal. According to the "Global Times", citing Japan's "Yomiuri Shimbun", the well-known Japanese pharmaceutical company Far East, after producing insufficient ingredients of the gastrointestinal medicine Zhenglu pills, was ordered by the Toyama County Government to stop production and sales for 30 years after falsifying data for shipment.
With a history of more than 100 years, Shoro Maru has been popular for its ability to treat gastrointestinal discomfort and has been sold both in Japan and abroad. However, who would have thought that behind this trusted drug, there would be such a terrifying secret.
In the process of producing this best-selling drug, in order to cover up the truth about the lack of ingredients, Jidong Pharmaceutical Company did not hesitate to fabricate false test results and bring substandard products to the market.
The exposure of this scandal is undoubtedly a heavy blow to the Japanese pharmaceutical industry. As a standing medicine for many families, the safety of Zhenglu pills is directly related to the vital interests of consumers. The behavior of Jidong Pharmaceutical Company is undoubtedly an extreme disregard for and trampling on the rights and interests of consumers.
In the face of this scandal, the Toyama prefectural government took decisive action and ordered Gokuto Pharmaceutical to stop manufacturing pharmaceuticals for 23 days and stop selling them for 22 days from April 30 this year. Far East was also quick to respond, voluntarily recalling 5.16 million products and publicly admitting that falsifying test results has been going on for at least 30 years.
The company's executives said that this was a serious neglect of the regulations, and they were deeply guilty of it, and sincerely apologized to the public and all parties involved. The incident not only raised serious questions about the credibility of Far East Pharmaceutical, but also plunged the entire Japanese pharmaceutical industry into a crisis of confidence.
We hope that this incident can cause deep reflection on the entire industry, strengthen supervision, ensure the quality and safety of drugs, and safeguard the legitimate rights and interests of consumers. At the same time, consumers are also reminded to be vigilant when choosing drugs, do not blindly believe in advertising, and ensure their own health and safety.
Recently, Japan's "Yomiuri Shimbun" exposed the scandal that shocked the pharmaceutical industry, shocking the world. According to reports, the well-known pharmaceutical company Jidong was ordered by the Toyama Prefectural Government to stop production and sales of the gastrointestinal drug "Zhenglu Pill" because of the insufficient ingredients in the production of the gastrointestinal drug "Zhenglu Pill" and falsifying the relevant data before shipment.
This incident not only revealed the serious misconduct in the manufacturing process of Jidong, but also aroused widespread public concern about drug safety issues. In addition to falsifying data, Far East was also found to have committed other violations of laws and regulations.
When purchasing raw materials for four gastrointestinal medicines, including "Zhenglu Pill", Jidong did not conduct the necessary quality tests, but directly used the test data provided by the raw material manufacturer. This behavior not only violates the basic norms of drug production, but also is extremely irresponsible for the health and safety of consumers. although
However, there have been no reports of personal health damage from consumers so far, but the incident has caused great public unease. The inappropriate manufacturing process that has occurred in Toyama Prefecture in recent years has also raised questions about the local drug production regulatory system.
It is worth noting that the administrative punishment imposed by the county government is not an isolated case. According to statistics, this is the seventh case of improper manufacturing by a pharmaceutical company in Toyama Prefecture in the past five years. This series of incidents not only harmed the interests of consumers, but also seriously damaged the reputation of the Japanese pharmaceutical industry.
Not long ago, Kobayashi Pharmaceutical, another well-known Japanese pharmaceutical company, also exposed similar problems. As of April 24, five people had died and 257 people had been hospitalized as a result of the company's health supplements containing red yeast rice, which had caused damage to consumers' health. This incident has aroused widespread concern and deep reflection from all walks of life.
Drugs are special commodities related to the lives and health of the people, and their safety and effectiveness must be strictly guaranteed. The successive exposures of Japanese pharmaceutical companies Far East and Kobayashi Pharmaceutical have undoubtedly sounded the alarm for global drug safety supervision.
We call on relevant departments to strengthen supervision, crack down on illegal acts in the process of drug production, and ensure the safety of drug use by the people. At the same time, it is also hoped that consumers will be vigilant, choose formal channels to buy drugs, and jointly safeguard their own health rights and interests.